1. Academic Validation
  2. Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates

Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates

  • Bioconjug Chem. 2023 Oct 18;34(10):1835-1850. doi: 10.1021/acs.bioconjchem.3c00354.
Christopher C Marvin 1 Adrian D Hobson 2 Michael McPherson 2 Theresa A Dunstan 2 Thomas R Vargo 2 Martin E Hayes 2 Margaret M Fettis 2 Agnieszka Bischoff 2 Lu Wang 2 Lu Wang 2 Axel Hernandez Jr 2 Ying Jia 2 Jason Z Oh 2 Yu Tian 2
Affiliations

Affiliations

  • 1 AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States.
  • 2 AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States.
Abstract

Antibody-drug conjugates consist of potent small-molecule payloads linked to a targeting antibody. Payloads must possess a viable functional group by which a linker for conjugation can be attached. Linker-attachment options remain limited for the connection to payloads via hydroxyl groups. A releasing group based on 2-aminopyridine was developed to enable stable attachment of para-aminobenzyl carbamate (PABC) linkers to the C21-hydroxyl group of budesonide, a Glucocorticoid Receptor Agonist. Payload release involves a cascade of two self-immolative events that are initiated by the protease-mediated cleavage of the dipeptide-PABC bond. Budesonide release rates were determined for a series of payload-linker intermediates in buffered solution at pH 7.4 and 5.4, leading to the identification of 2-aminopyridine as the preferred releasing group. Addition of a poly(ethylene glycol) group improved linker hydrophilicity, thereby providing CD19-budesonide ADCs with suitable properties. ADC23 demonstrated targeted delivery of budesonide to CD19-expressing cells and inhibited B-cell activation in mice.

Figures